FIGURE 1.

Seroconversion 3 months after SARS‐CoV‐2 vaccination differs among disease‐ modifying treatment (DMT) categories (a) and substances (b). Lower dotted line indicates the level of seropositivity and upper dotted line indicates the upper limit of antibody level at 384 BAU/ml in (c) and (d). ATZ, alemtuzumab; BAU/ml, binding antibody units per milliliter; CD20, anti‐cluster of differentiation 20 monoclonal antibodies (ocrelizumab or rituximab); CLA, cladribine; DMF, dimethyl fumarate; DMT, disease‐modifying treatment; GLAT, glatiramer acetate; IFNb, interferon‐beta preparations; IM‐DMT, immunomodulating DMT (dimethyl fumarate, glatiramer acetate, interferon‐beta preparations, natalizumab and teriflunomide); IS‐DMT, immunosuppressive DMT (alemtuzumab, cladribine, fingolimod, ocrelizumab, ozanimod, siponimod or rituximab); N‐DMT, no DMT (untreated); NTZ, natalizumab; S1PM, sphingosine 1 receptor modulators (fingolimod, ozanimod, siponimod); TERI, teriflunomide [Colour figure can be viewed at wileyonlinelibrary.com]